Bimzelx (bimekizumab-bkzx) has taken a step closer to US approval, with the US regulator accepting a supplemental Biologics License Application in hidradenitis 4 April 2024
Adding to recent setbacks in the development of Leqembi (lecanemab), US firm Biogen (Nasdaq: BIIB) has revealed a filing for a subcutaneous formulation will be 3 April 2024
An attempt from the conservative Alliance for Hippocratic Medicine to ban mifepristone, a medicine used to induce an abortion, threatens to undermine confidence 27 March 2024
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.